The latter were originally developed as potential therapeutics for the treatment of neurological disorders by means of inhibiting the enzymatic activity of PSMA residing in the central/peripheral nervous system, also known as glutamate carboxypeptidase II (GCPII) or N-acetylated α-linked acidic dipeptidase (NAALADase) (27,28). Here, FOLH1 is linked to nervous system disorder.